Benzinga | Oct 19, 2021 09:00AM EDT

Maxim Group Upgrades Indaptus Therapeutics to Buy, Announces $16 Price Target

Maxim Group analyst Jason McCarthy upgrades Indaptus Therapeutics (NASDAQ:INDP) from Hold to Buy and announces $16 price target.